Nuvation Bio NUVB Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One at other companies
Where this comes from
Reported directly by Nuvation Bio in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost.
The official record: Nuvation Bio’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nuvation Bio's debt securities, available-for-sale, amortized cost, maturity, allocated and single maturity date, year one.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nuvation Bio's debt securities, available-for-sale, amortized cost, maturity, allocated and single maturity date, year one?
- Nuvation Bio (NUVB) reported debt securities, available-for-sale, amortized cost, maturity, allocated and single maturity date, year one of $222.75M in Q4 2025.
- How has Nuvation Bio's debt securities, available-for-sale, amortized cost, maturity, allocated and single maturity date, year one changed year-over-year?
- Nuvation Bio's debt securities, available-for-sale, amortized cost, maturity, allocated and single maturity date, year one decreased by 42.0% year-over-year, from $384.03M to $222.75M.
- What is the long-term trend for Nuvation Bio's debt securities, available-for-sale, amortized cost, maturity, allocated and single maturity date, year one?
- Over 4 years (2021 to 2025), Nuvation Bio's debt securities, available-for-sale, amortized cost, maturity, allocated and single maturity date, year one has grown at a -9.9% compound annual growth rate (CAGR), from $337.83M to $222.75M.